Document Detail


Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the Food and Drug Administration.
MedLine Citation:
PMID:  1477244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This guideline addresses the evaluation of new antimycobacterial drugs in the treatment and prevention (secondary prophylaxis) of infection by M. tuberculosis. Patients may be enrolled in clinical trials on the basis of clinical and/or microbiological criteria. A therapeutic regimen will likely include a combination of drugs; a randomized, active-control, comparative clinical trial is recommended. If appropriate samples can be obtained for culture during follow-up without placing the patient at unwarranted risk, the assessment of microbiological outcome is paramount. Prophylaxis will probably require a single drug, and a similar study design is preferred.
Authors:
P Hopewell; M Cynamon; J Starke; M Iseman; R O'Brien
Related Documents :
23732954 - Substituted cathinone products: a new trend in "bath salts" and other designer stimulan...
24862204 - Antiepileptic activity of preferential inhibitors of persistent sodium current.
9766614 - Clinical development of atypical antipsychotics: research design and evaluation. collab...
3054684 - A multicenter evaluation of levobunolol (vistagan) in germany.
17274654 - Effect of tyrosine-derived triblock copolymer compositions on nanosphere self-assembly ...
9615864 - Drug resistance to topoisomerase ii inhibitors.
Publication Detail:
Type:  Guideline; Journal Article; Practice Guideline; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  15 Suppl 1     ISSN:  1058-4838     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  1992 Nov 
Date Detail:
Created Date:  1993-02-05     Completed Date:  1993-02-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S282-95     Citation Subset:  IM    
Affiliation:
Chest Service, San Francisco General Hospital, California 94110.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antitubercular Agents / therapeutic use*
Child
Clinical Protocols / standards
Clinical Trials as Topic / standards*
Clinical Trials, Phase I as Topic / standards
Clinical Trials, Phase II as Topic / standards
Clinical Trials, Phase III as Topic / standards
Humans
Research Design
Tuberculosis / drug therapy*
Grant Support
ID/Acronym/Agency:
HHS 223-88-1301/HS/AHRQ HHS
Chemical
Reg. No./Substance:
0/Antitubercular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Disea...
Next Document:  Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the ...